Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3DNA-based miR146b-5p therapy
- Development stage
- Unknown
- Modality
- Nanoparticles → Drug Delivery Systems, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Parenteral, Intracerebral Administration
01
Overview
3DNA-based miR146b-5p therapy is an experimental therapeutic approach that utilizes a synthetic microRNA (miRNA) mimic—specifically, miR-146b-5p—delivered via a DNA nanocarrier platform known as "3DNA." This targeted delivery system is designed to increase the expression of miR-146b-5p in specific cell types, such as microglia in the central nervous system. The mechanism of action involves modulating inflammatory responses by downregulating pro-inflammatory signaling pathways (notably through suppression of IRAK1), thereby reducing microglial activation and neuroinflammation. In preclinical models, this strategy has shown efficacy in preventing hypomyelination and cognitive deficits induced by perinatal inflammation, suggesting potential for treating neurodevelopmental injuries like white matter injury (WMI) in premature infants[1].
- Other names
- 3DNA miRNA-146b-5p therapy3DNA nanocarrier miR-146b-5p delivery
02
Targets
IRAK1 (Interleukin-1 receptor-associated kinase 1)RELA (Nuclear Factor Kappa B Subunit p65)TRAF6
Beyond the preview
Go deeper on 3DNA-based miR146b-5p therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 3DNA-based miR146b-5p therapy.